WILMINGTON, DE — Incyte Corp. (Nasdaq: INCY) will present early clinical data on two cancer treatments that have advanced into Phase 3 testing at the ESMO Congress in Madrid this October, giving investors a closer look at programs targeting pancreatic and colorectal cancers.
The Wilmington-based drugmaker scheduled six presentations for the European Society for Medical Oncology meeting, which runs from Oct. 23 through Oct. 27.
Four rapid oral presentations will cover investigational treatments from Incyte’s solid-tumor pipeline. Two additional posters will examine survival results for the approved immunotherapy retifanlimab and the design of a Phase 3 ovarian cancer study.
The most closely watched data are likely to involve INCB161734, an oral drug designed to inhibit KRAS G12D, a mutation found in several difficult-to-treat cancers.
One presentation will report safety and efficacy results from INCB161734 used alone or with cetuximab in patients with advanced or metastatic colorectal cancer. The session is scheduled for Oct. 25 and carries abstract number 1007RO.
A second presentation will evaluate the drug in combination with chemotherapy for advanced or metastatic pancreatic ductal adenocarcinoma. Those findings are scheduled for Oct. 26 under abstract number 3137RO.
Incyte is already evaluating INCB161734 in a Phase 3 program as an initial treatment for advanced pancreatic ductal adenocarcinoma, according to the company.
Another rapid oral presentation will cover INCA33890, an experimental bispecific antibody designed to target TGFβR2 and PD-1 simultaneously.
The study combines INCA33890 with standard cancer therapies in patients with microsatellite-stable colorectal cancer, a disease setting that has generally proved resistant to existing immunotherapies. The presentation is scheduled for Oct. 24 under abstract number 1954RO.
The drug is also being studied in an ongoing Phase 3 program as a first-line treatment for microsatellite-stable colorectal cancer.
Incyte will present preliminary efficacy data for INCB123667, a CDK2 inhibitor, combined with bevacizumab in recurrent epithelial ovarian cancer. That presentation is scheduled for Oct. 23 under abstract number 1241RO.
The company will also provide the final overall-survival results from POD1UM-303, also known as InterAACT-2, a Phase 3 trial of retifanlimab with carboplatin and paclitaxel as an initial treatment for advanced squamous anal cancer.
Those results will be presented Oct. 25 under abstract number 3536P.
A separate poster will outline the MAESTRA 3 Phase 3 trial, which is comparing INCB123667 plus bevacizumab with bevacizumab alone as first-line maintenance therapy for advanced ovarian, fallopian tube or primary peritoneal cancer that overexpresses cyclin E1.
The randomized, double-blind study is also identified as GOG-3146 and ENGOT-OV106. Its trial-design poster is scheduled for Oct. 26 under abstract number 1336TiP.
Incyte did not disclose the clinical results ahead of the conference. The presentations will provide the first detailed assessment of the reported findings and may help determine whether the company’s solid-tumor pipeline can expand its oncology business beyond its established products.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.